Latest Archives - Page 7 of 8 - Solving Kids' Cancer

Sarcoma in Children

A sarcoma is a cancer that develops in bone or soft tissue. Soft tissue is the connective tissue between body parts and organs and can include muscles, tendons, fat, bone and cartilage, blood vessels, and lymph vessels. Sarcomas can be found anywhere in the body, but they are most often found in the arms, legs, chest, or abdomen. Pediatric sarcoma is sarcoma occurring in children, and accounts for approximately 15% of pediatric cancer cases, with 1,500 to 1,700 new cases diagnosed each year.

Neuroblastoma Cancer Tumor in Children

Neuroblastoma is diagnosed in approximately 800 children in the United States each year. Ninety percent of cases occur in children under five years old, though the average age of diagnosis is between one and two years old. Still, because neuroblastomas form from fetal nerve cells, children as young as newborns can develop tumors, and neuroblastoma accounts for 50% of all cancer cases in infants.

Landmark Transatlantic Trial for Children with High-Risk Neuroblastoma Funded by Parent-Led Charities

In a landmark in pediatric oncology research, children with high-risk neuroblastoma across Europe and North America will be treated together for the first time, following the award of $1.4M to fund a new transatlantic clinical trial.

Rare Brain Tumors in Kids

Brain and spinal cord tumors, also known as central nervous system (CNS) tumors, are the most common type of solid tumors affecting children. Brain tumors make up about 15% of pediatric cancers, and are the second most commonly diagnosed cancer in children and now, the deadliest type of childhood cancer, ahead of leukemia.

Clinical Trial Harnesses Power of Natural Killer Cells to Treat Neuroblastoma

Solving Kids’ Cancer, The Catherine Elizabeth Blair Memorial Foundation, and Wade’s Army awarded a $136,000 grant to support the novel immunotherapy clinical trial for childhood cancer. Researchers will use a humanized monoclonal antibody linked to IL2, known as hu14.18-IL2, which specifically targets neuroblastoma tumor cells and binds to them, while the IL2 activates NK cells…

A Welcome Gift for the Pediatric Brain Tumor Community

What began as a proposal for a four-center US-based clinical trial of promising combination therapy for children battling brain tumors, has expanded into a large-scale clinical trial at 58 centers in 13 countries, that brings new hope to children across the globe.

Targeted Therapy for Children with ALK-Driven Neuroblastoma

Lorlatinib, an investigational drug candidate currently in late-stage clinical development for the treatment of lung cancer may also prove effective for the treatment of the pediatric cancer neuroblastoma. Solving Kids’ Cancer is leading an international effort of like-minded nonprofits to provide nearly $400,000 of collaborative funding for an innovative clinical trial to bring a potentially life-saving therapy to kids.

Advocacy in Action

Solving Kids’ Cancer was the first charity to ever go against the UK healthcare system without a pharmaceutical company involved. As a result, the National Institute for Health and Care Excellence (NICE) recently announced that it has upheld SKC’s appeal against the Institute’s decision not to recommend dinutuximab for treating high-risk neuroblastoma.

Precision Medicine Advances for Children With Neuroblastoma

Solving Kids’ Cancer (SKC) together with Wade’s Army announce their joint financial support of this Phase 1 clinical trial to test the safety and efficacy of various investigational drugs that will leverage precision medicine for children with neuroblastoma. This Next Generation Personalized Neuroblastoma Therapy – also known as NEPENTHE (Greek for “medicine for sorrow”) – is the first precision medicine trial for children that will robustly analyze the genomics of their cancer and use combinations of investigational drugs to target specific mutations in their tumors.

Children with High Grade Brain Tumors will be able to Receive Cutting-edge Oncolytic Virus Therapy

The Andrew McDonough B+ Foundation (The B+ Foundation) and Solving Kids’ Cancer (SKC) presented a check for $208,500 to Dr. Matthias Gromeier and Dr. Eric Thompson at the Preston Robert Tisch Brain Tumor Center at Duke, to co-fund an exciting new immunotherapy trial for children with deadly brain tumors.